ClinicalTrials.gg
TerminatedNCT04748848Updated Mar 2, 2023

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

A Phase 1 interventional study of CC-90011 and Venetoclax in Leukemia, Myeloid, sponsored by Celgene. Terminated at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.

Primary conditionLeukemia, Myeloid, AcuteRegistry: Leukemia, MyeloidReclassifiedWhy we changed it
Registry
Leukemia, Myeloid — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's title name Leukemia, Myeloid, Acute, a narrower term within Leukemia, Myeloid.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business objectives have changed.

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
196th of 202
1 · median 57
Started
2021
with 14 others
Phase 1
38 of 202
16 open now
Registered
57th of 202
by date

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 196th largest by enrollment, is one of 15 that started in 2021, is one of 38 in phase 1, and was the 57th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

CC-90011-AML-002 is a Phase 1/2, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently with Venetoclax and Azacitidine. This study will include 3 parts: a dose escalation part in R/R AML, a dose escalation part in ndAML (treatment-naïve participants with AML who are ≥ 75 years of age or are ≥ 18 to 74 years of age and otherwise not eligible for intensive induction chemotherapy), and a randomized dose expansion part in ndAML of Venetoclax and Azacitidine with or without CC-90011.

03

Conditions studied

  • Leukemia, Myeloid

Browse trials for

Keywords

  • Acute Myeloid Leukemia
  • CC-90011
  • Venetoclax
  • Azacitidine
  • LSD-1 inhibitor
  • Minimal residual disease
04

In context

Leukemia, Myeloid, Acute Reclassified

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

This study's enrollment of 1 is below the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myeloid. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must satisfy the following criteria to be enrolled in the study:

All participants (Parts I, II, and III):

  1. Participant must understand and voluntarily sign an Form (ICF) prior to any study-related assessments/procedures being conducted.
  1. Participant must have a projected of at least 12 weeks. 4. Participant has (ECOG) performance status of 0 to 2.
  1. Participants must have the required protocol baseline laboratory values 6. Participant has adequate organ function 7. Participant must be able and willing to undergo hospitalization, hydration, and treatment with a uric acid-reducing agent prior to the first dose of venetoclax and during Cycle 1.

Part I only:

  1. acute myeloid leukemia (AML) as defined by the World Health Organization (WHO) Classification and is ≥ 18 years of age at the time of signing the ICF who are not eligible to receive further intensive therapy and:
  1. Has failed to have a complete remission (CR) or CR with incomplete hematologic recovery (Cri) after induction plus reinduction with intensive chemotherapy (anthracycline plus cytarabine containing regimens) or 2 cycles of low intensity therapy (either 2 cycles of the same regimen or 1 cycle of 2 different regimens) OR
  2. Has relapsed from CR from either intensive or low-intensity therapy. Participants with second relapse are also eligible

Part II and Part III only:

  1. confirmed treatment naïve Acute myeloid leukemia (AML) as defined by the 2008 World Health Organization (WHO) Classification, including secondary AML and therapy related AML, and is ≥ 75 years of age at the time of signing the ICF, or is ≥ 18 to 74 years at the time of signing the ICF with comorbidities precluding the use of intensive induction chemotherapy 10. Participant has not received prior therapy for AML with the exception of hydroxyurea to treat hyperleukocytosis.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a participant from enrollment:

All participants (Parts I, II, and III):

  1. Participant is suspected or proven to have acute promyelocytic leukemia (APL) based on morphology, immunophenotype, molecular assay, or karyotype.
  2. Participant has favorable risk cytogenetics
  3. Participants with AML who may receive fms-like tyrosine kinase 3 (FLT3) inhibitor directed therapy.
  4. Participant has or is suspected of having active central nervous system (CNS) involvement.
  5. Participant has an active, uncontrolled infection except participants with infection under active treatment and controlled with antibiotics, antifungals, or antivirals are eligible.
  6. Participant with prior hematopoietic stem cell transplant (HSCT) who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant related side effects).
  7. Participant had prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing.
  8. Participants on systemic therapy post HSCT at the time of screening, or with (GVHD). The use of topical for ongoing skin or ocular GVHD is permitted.
  9. Participant has immediate life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection, uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation. The participant should be afebrile for at least 72 hours.
  10. Participants requiring treatment with strong or moderate inhibitors/inducers.
  11. Participant has ongoing treatment with chronic, therapeutic dosing of anticoagulants.
  12. Participant has a history of concurrent secondary cancers requiring active, ongoing systemic treatment.
  13. Participant has known (HIV) infection.
  14. Participant has known chronic active virus (HBV) or virus (HCV).

    1. Participant who is seropositive due to HBV vaccination is eligible.
    2. Participant who has no active viral infection and is under adequate prophylaxis against HBV reactivation is eligible.
  15. Participant is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
  16. Participant has impaired cardiac function or clinically significant cardiac diseases
  17. Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or Star fruit within 3 days prior to first venetoclax dose through last dose of venetoclax.
  18. Pregnant women are excluded from this study due to potential teratogenic and/or abortifacient effect of this therapy. Nursing mothers should stop breastfeeding in order to be eligible due to potential risk for Adverse Events (AEs) in a nursing infant.
  19. Participant has had previous treatment with a lysine-specific demethylase 1A (LSD1) inhibitor.
  20. Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
  21. Participant has any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.
  22. Participant has any condition that confounds the ability to interpret data from the study.
  23. Participant received live COVID-19 vaccines within 30 days prior to initiation of study treatment
  24. Participants currently in other interventional trials, including those for COVID-19, may not participate in BMS clinical trials until the protocol specific is achieved. If a study participant has received an COVID-19 vaccine or other investigational product designed to treat or prevent COVID-19 prior to screening, enrollment must be delayed until the biologic impact of the vaccine or investigational product is stabilized, as determined by discussion between the Investigator and the Medical Monitor.

    Part I only:

  25. Participant had prior treatment with venetoclax for AML, either as monotherapy or in combination with other agents.

    Part II and Part III only:

  26. Participant had prior treatment with hypomethylating agent (HMA) or chemotherapy for antecedent hematologic disorders. Prior treatment with hydroxyurea is permitted.
  27. Participant has received systemic anticancer therapy (including investigational therapy), radiotherapy, or immunotherapy \< 14 days or 5 half-lives, whichever is shorter, prior to the first dose of CC-90011.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    CC-90011 in combination with Venetoclax and Azacitidine in Dose Escalation

    CC-90011 in combination with venetoclax and azacitidine in dose escalation

    Drug: CC-90011 · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Venetoclax and Azacitidine

    Venetoclax and Azacitidine control arm in dose expansion. The participants will be randomized to the treatment arm or control arm at a 2:1 ratio.

    Drug: Azacitidine · Drug: Venetoclax

  • Experimental
    CC-90011 in combination with Venetoclax and Azacitidine in Dose Expansion

    CC-90011 in combination with venetoclax and azacitidine in dose expansion

    Drug: Venetoclax · Drug: Azacitidine · Drug: CC-90011

Interventions

  • CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.

  • Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.

  • Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2

  • Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle

  • CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.

07

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE

    Time frame: From ICF signature until 28 days after last dose of CC- 90011 and all combination agents

  2. Recommended Phase 2 dose (RP2D)

    The RP2D will include evaluation of DLTs and MTD using NCI CTCAE criteria

    Time frame: Up to approximately Cycle 1 (each cycle is 28 days)

Secondary outcomes

  1. Complete remission (CR) Rate

    Defined as the rate of achieving CR (as assessed by the Investigator and by programmatic outputs by the Sponsor)

    Time frame: Up to approximately 10 months

  2. Complete remission with partial hematologic recovery (CRh) Rate

    Defined as the rate of achieving CRh (as assessed by the Investigator and by programmatic outputs by the Sponsor)

    Time frame: Up to approximately 2 years

  3. Overall response rate (ORR)

    Defined as the rate of achieving CR/CRMRD-/CRi/PR/MLFS

    Time frame: Up to approximately 2 years

  4. Duration of response (CR)

    Time from the first CR to the date of documented disease relapse or death, whichever is earlier.

    Time frame: Up to approximately 2 years

  5. Duration of response (CR/CRh)

    Time from the first CR or CRh to the date of documented disease relapse or death, whichever is earlier.

    Time frame: Up to approximately 2 years

  6. Duration of response (CR/ CRMRD-/ CRi/ PR/MLFS)

    Time from the first CR, CRMRD-, CRi, PR or MLFS to the date of documented disease relapse, progression, or death, whichever is earlier.

    Time frame: Up to approximately 2 years

  7. Event-free survival (EFs)_Part III Only

    Time from study randomization to the date of treatment failure, relapse from CR or death from any cause, whichever comes first.

    Time frame: Up to approximately 2 years

  8. Overall survival (OS)_Part III Only

    Time from study randomization to the date of death due to any cause.

    Time frame: Up to approximately 2 years

  9. Minimal residual disease (MRD) Response Rate_Part II and III only

    The rate of having at least a one log reduction in disease burden or an MRD negative (10-3) test result.

    Time frame: Up to approximately 2 years

  10. Minimal residual disease (MRD) Conversion Rate_Part II and III Only

    The rate of participants achieving MRD negativity (10-3) at any time on therapy.

    Time frame: Up to approximately 2 years

  11. Complete response with incomplete hematologic recovery (CRi) rate

    Defined as the rate of achieving CRi (as assessed by the Investigator and by programmatic outputs by the Sponsor)

    Time frame: Up to approximately 2 years

  12. Duration of response (CR/CRi)

    Time from the first CR or CRi to the date of documented disease relapse or death, whichever is earlier.

    Time frame: Up to approximately 2 years

08

Study locations

17 sites
  • Local Institution - 110
    Duarte, California 91010-301, United States
  • Local Institution - 103
    New Haven, Connecticut 06510, United States
  • Local Institution - 108
    Miami, Florida 33136, United States
  • Local Institution - 111
    Chicago, Illinois 60611, United States
  • Local Institution - 121
    New York, New York 10029, United States
  • Local Institution - 118
    Durham, North Carolina 27710, United States
  • Local Institution - 116
    Cleveland, Ohio 44195, United States
  • Local Institution - 115
    Columbus, Ohio 43210, United States
  • Local Institution - 104
    Dallas, Texas 75246, United States
  • Local Institution - 101
    Houston, Texas 77030, United States
  • Local Institution - 120
    Seattle, Washington 98104, United States
  • Local Institution - 202
    Gent, 9000, Belgium
  • Local Institution - 401
    Villejuif CEDEX, 94805, France
  • Local Institution - 803
    Barcelona, 08035, Spain
  • Local Institution - 800
    Barcelona, 08907, Spain
  • Local Institution - 802
    Madrid, 28007, Spain
  • Local Institution - 801
    Sevilla, 41013, Spain
09

References and documents

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Mar 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 10, 2021
StartActual
Oct 14, 2021
Primary completionActual
Mar 9, 2022
CompletionActual
Mar 9, 2022
Last update
Mar 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04748848
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Feb 10, 2021
Start date
Oct 14, 2021
Primary completion
Mar 9, 2022
Completion
Mar 9, 2022
Last update
Mar 2, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Azacitidine

Start the discussion